[
  {
    "ts": "2025-12-02T09:00:00+00:00",
    "headline": "Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy",
    "summary": "Antengene Corporation Limited (\"Antengene\", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for the Phase Ib/II CLINCH-2 study evaluating ATG-022 (",
    "url": "https://finance.yahoo.com/news/antengene-announces-ind-approval-china-090000940.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "1fd5079a-afb0-304a-be8d-b909c9e87124",
      "content": {
        "id": "1fd5079a-afb0-304a-be8d-b909c9e87124",
        "contentType": "STORY",
        "title": "Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy",
        "description": "",
        "summary": "Antengene Corporation Limited (\"Antengene\", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the China National Medical Products Administration (NMPA) has approved the investigational new drug (IND) application for the Phase Ib/II CLINCH-2 study evaluating ATG-022 (",
        "pubDate": "2025-12-02T09:00:00Z",
        "displayTime": "2025-12-02T09:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/80e76465ee715e6705d5fcce90b9f583",
          "originalWidth": 400,
          "originalHeight": 170,
          "caption": "Logo (PRNewsfoto/Antengene Corporation Limited)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iX4d3zH6.489mYmi5zPGYg--~B/aD0xNzA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/80e76465ee715e6705d5fcce90b9f583.cf.webp",
              "width": 400,
              "height": 170,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/p3TrWaua._04_VbJue7uzw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/80e76465ee715e6705d5fcce90b9f583.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/antengene-announces-ind-approval-china-090000940.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/antengene-announces-ind-approval-china-090000940.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "6996.HK"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-02T04:37:27+00:00",
    "headline": "1 Value Stock to Target This Week and 2 We Question",
    "summary": "The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.",
    "url": "https://finance.yahoo.com/news/1-value-stock-target-week-043727752.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "ba4dcfc0-1b33-340c-a707-6d2dacbd9a1f",
      "content": {
        "id": "ba4dcfc0-1b33-340c-a707-6d2dacbd9a1f",
        "contentType": "STORY",
        "title": "1 Value Stock to Target This Week and 2 We Question",
        "description": "",
        "summary": "The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.",
        "pubDate": "2025-12-02T04:37:27Z",
        "displayTime": "2025-12-02T04:37:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/a5a26cccd4a376adb3c4555284e9f6e6",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "SBH Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kMiKj.4u9vLWoG18YxdFQw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/a5a26cccd4a376adb3c4555284e9f6e6.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/K9qHBVFGV9ABPTF8GFabkw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/a5a26cccd4a376adb3c4555284e9f6e6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/1-value-stock-target-week-043727752.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-value-stock-target-week-043727752.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "APOG"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "SBH"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-02T12:14:37+00:00",
    "headline": "Has Merck’s Valuation Shifted After Key Pipeline Updates and an 18% Stock Jump?",
    "summary": "Ever wondered if Merck’s current share price actually reflects its real worth? You’re not alone, and uncovering value can make all the difference for your portfolio. Merck’s stock has jumped 18.4% over the last 30 days, even though it’s dipped 3.6% over the last week. This shows just how quickly market sentiment can shift. This recent volatility comes as investors react to a wave of positive pipeline updates and strategic partnership announcements, which have fueled fresh optimism about...",
    "url": "https://finance.yahoo.com/news/merck-valuation-shifted-key-pipeline-121437696.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "17456c67-f150-39dd-bced-34e99b2fccbc",
      "content": {
        "id": "17456c67-f150-39dd-bced-34e99b2fccbc",
        "contentType": "STORY",
        "title": "Has Merck’s Valuation Shifted After Key Pipeline Updates and an 18% Stock Jump?",
        "description": "",
        "summary": "Ever wondered if Merck’s current share price actually reflects its real worth? You’re not alone, and uncovering value can make all the difference for your portfolio. Merck’s stock has jumped 18.4% over the last 30 days, even though it’s dipped 3.6% over the last week. This shows just how quickly market sentiment can shift. This recent volatility comes as investors react to a wave of positive pipeline updates and strategic partnership announcements, which have fueled fresh optimism about...",
        "pubDate": "2025-12-02T12:14:37Z",
        "displayTime": "2025-12-02T12:14:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-valuation-shifted-key-pipeline-121437696.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-valuation-shifted-key-pipeline-121437696.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-02T13:12:24+00:00",
    "headline": "Vaccine stocks brace for shock waves at this week’s ACIP meeting",
    "summary": "Investing.com -- Bernstein warned in a note Tuesday that “shock waves are expected at the ACIP meeting this week,” citing a series of unusual developments that could have implications for Merck, Pfizer and Moderna.",
    "url": "https://finance.yahoo.com/news/vaccine-stocks-brace-shock-waves-131224558.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "0f6df930-08e0-3ac1-b456-99e66c8e2b9b",
      "content": {
        "id": "0f6df930-08e0-3ac1-b456-99e66c8e2b9b",
        "contentType": "STORY",
        "title": "Vaccine stocks brace for shock waves at this week’s ACIP meeting",
        "description": "",
        "summary": "Investing.com -- Bernstein warned in a note Tuesday that “shock waves are expected at the ACIP meeting this week,” citing a series of unusual developments that could have implications for Merck, Pfizer and Moderna.",
        "pubDate": "2025-12-02T13:12:24Z",
        "displayTime": "2025-12-02T13:12:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vaccine-stocks-brace-shock-waves-131224558.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vaccine-stocks-brace-shock-waves-131224558.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-02T15:30:00+00:00",
    "headline": "Nanopharmaceuticals Research Report 2025: Market to Reach $104.58 Billion by 2030, Driven by Rising Chronic Disease Burden and Growing Investment in Regenerative Medicine and Nanotechnology Drugs",
    "summary": "The nanopharmaceuticals market presents opportunities in addressing chronic diseases through enhanced targeted therapies and bioavailability. Personalization in treatments, particularly in oncology, is a key trend. However, high R&D costs and regulatory hurdles pose challenges. Key players include Merck, Pfizer, and Novartis. Nanopharmaceuticals Market Nanopharmaceuticals Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The \"Nanopharmaceuticals Market - Global Industry Size, Share, Trends, Oppor",
    "url": "https://finance.yahoo.com/news/nanopharmaceuticals-research-report-2025-market-153000292.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "ddd41f85-4b4d-3bce-90c2-0f4cba5b16a2",
      "content": {
        "id": "ddd41f85-4b4d-3bce-90c2-0f4cba5b16a2",
        "contentType": "STORY",
        "title": "Nanopharmaceuticals Research Report 2025: Market to Reach $104.58 Billion by 2030, Driven by Rising Chronic Disease Burden and Growing Investment in Regenerative Medicine and Nanotechnology Drugs",
        "description": "",
        "summary": "The nanopharmaceuticals market presents opportunities in addressing chronic diseases through enhanced targeted therapies and bioavailability. Personalization in treatments, particularly in oncology, is a key trend. However, high R&D costs and regulatory hurdles pose challenges. Key players include Merck, Pfizer, and Novartis. Nanopharmaceuticals Market Nanopharmaceuticals Market Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The \"Nanopharmaceuticals Market - Global Industry Size, Share, Trends, Oppor",
        "pubDate": "2025-12-02T15:30:00Z",
        "displayTime": "2025-12-02T15:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/b223a5ddc062f0eb6d7821bb77d80756",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Nanopharmaceuticals Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qrKLm.Rj1pX387tgl8rMYQ--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b223a5ddc062f0eb6d7821bb77d80756.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NDLorc_s9i8YXneqzKgvow--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/b223a5ddc062f0eb6d7821bb77d80756.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nanopharmaceuticals-research-report-2025-market-153000292.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nanopharmaceuticals-research-report-2025-market-153000292.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-02T14:45:19+00:00",
    "headline": "Why Merck (MRK) is a Top Growth Stock for the Long-Term",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finance.yahoo.com/news/why-merck-mrk-top-growth-144519615.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "3803108c-190d-334e-a96b-e37b49d17a19",
      "content": {
        "id": "3803108c-190d-334e-a96b-e37b49d17a19",
        "contentType": "STORY",
        "title": "Why Merck (MRK) is a Top Growth Stock for the Long-Term",
        "description": "",
        "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
        "pubDate": "2025-12-02T14:45:19Z",
        "displayTime": "2025-12-02T14:45:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85",
          "originalWidth": 900,
          "originalHeight": 636,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/eN0EvS2DQjGO_6Aa8hYV4w--~B/aD02MzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85.cf.webp",
              "width": 900,
              "height": 636,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IXPNK2bXbxtvuH6_.DBDbA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c6f98f4bf655bec3b199bc1a71b8b85.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-merck-mrk-top-growth-144519615.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-merck-mrk-top-growth-144519615.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-02T15:24:00+00:00",
    "headline": "Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure",
    "summary": "Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum.",
    "url": "https://finance.yahoo.com/news/pfizers-cancer-drugs-deliver-growth-152400012.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d3e3d388-1171-33cf-b6f6-b2a7a6cf2f52",
      "content": {
        "id": "d3e3d388-1171-33cf-b6f6-b2a7a6cf2f52",
        "contentType": "STORY",
        "title": "Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure",
        "description": "",
        "summary": "Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum.",
        "pubDate": "2025-12-02T15:24:00Z",
        "displayTime": "2025-12-02T15:24:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A9LQHlDmqgPJbKsotfjd8w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5.ym16dSp_UIlCHMRMZUw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizers-cancer-drugs-deliver-growth-152400012.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizers-cancer-drugs-deliver-growth-152400012.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]